| Company/Division name | Fujifilm Diosynth Biotechnologies |
| Parent company | Fujifilm Corporation |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2019 |
| Year reshoring implemented or to be implemented: | 2021 |
| Capital investment ($): | 120 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | College Station |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | gene therapy development |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Customer responsiveness improvement, Eco-system synergies, Skilled workforce availability/training, Other, expansion |
